UAE fast-tracks approval of Blenrep, pioneering treatment for multiple myeloma

CAR-T Digest - August 2020

12 August 2025: UAE fast-tracks approval of Blenrep, pioneering treatment for multiple myeloma

The UAE has approved Blenrep (Belantamab Mafodotin) as a treatment for relapsed or resistant multiple myeloma
UAE becomes the third country globally, after the UK and Japan, to approve the drug
The approval reflects the UAE’s commitment to fast-tracking access to advanced medical treatments
Multiple myeloma was the third most common cancer in the UAE in 2023, highlighting the urgency for new therapies
Blenrep targets and destroys myeloma cells while sparing healthy cells, potentially improving patients’ outcomes and quality of life